Press release
Type 1 Diabetes Pipeline Drugs Report 2025: Innovative Drug Developments and Ongoing Clinical Studies Uncovered
Explore our latest breakthroughs in Type 1 Diabetes Research. Learn more about our innovative pipeline today! @ Type 1 Diabetes Pipeline Outlook [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Type 1 Diabetes Pipeline Report
* On 03 October 2025, Creative Medical Technology Holdings Inc. conducted a study is a Phase I/IIa randomized, controlled clinical trial to evaluate CELZ-201 therapy as an intervention for the treatment of recent onset Type 1 Diabetes. The objective is to determine the safety and efficacy of CELZ-201 administration, based on the timing and dose of CELZ-201 treatment. Subjects who meet eligibility criteria will be randomized to treatment or control groups, in a 2:1 ratio. Subjects in the Group I (Treatment Group, n=12) will receive standard of care for type 1 diabetes and CELZ-201 within 1 month from enrollment (within 1 year of diagnosis). Subjects in Group II (Control Arm, n=6) and will receive enhanced standard of care for type 1 diabetes.
* On 01 October 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care.
* DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
* The leading Type 1 Diabetes Companies such as Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
* Promising Type 1 Diabetes Pipeline Therapies such as Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016 and others.
Stay informed about the cutting-edge advancements in Type 1 Diabetes treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Type 1 Diabetes Clinical Trials Assessment [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Type 1 Diabetes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Type 1 Diabetes Pipeline Report also highlights the unmet needs with respect to the Type 1 Diabetes.
Type 1 Diabetes Overview
Type 1 diabetes is an autoimmune disease where the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This results in a complete lack of insulin production, which is required for the body to regulate blood sugar levels. The exact cause of this autoimmune destruction is unknown, but it is believed to involve a combination of genetic and environmental factors.
Type 1 Diabetes Emerging Drugs Profile
* Insulin Efsitora Alfa: Eli Lilly and Company
LY3209590 ""Insulin Efsitora Alfa"" is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Type 1 Diabetes.
* Stem Cell Educator therapy: Throne Biotechnologies
Throne's Stem Cell Educator Therapy is designed to reverse the root causes of autoimmune diseases, such as diabetes and alopecia, by fundamentally "resetting" the immune system through a one-time dialysis-like treatment using CB-SC stem cells. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with Type 1 Diabetes.
* Frexalimab: Sanofi
Frexalimab (SAR441344) is a potentially first-in-class second generation investigational anti-CD40L antibody that blocks the costimulatory CD40/CD40L pathway which is important for activation and function of adaptive (T and B cells) and innate (macrophages/microglia and dendritic cells) immunity. Through this unique upstream mechanism of action, frexalimab has the potential to address both acute and chronic neuroinflammation in MS, without causing lymphocyte depletion. Sanofi is developing frexalimab under an exclusive license from ImmuNext. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Type 1 Diabetes.
* VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. It is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 is being investigated as an infusion into the hepatic portal vein and requires immunosuppressive therapy to protect the islet cells from immune rejection. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Type 1 Diabetes.
* MTX-101: Mozart Therapeutics
MTX-101 is a bispecific autoimmune checkpoint inhibitor. Its dual configuration binds the CD8 Treg receptors, KIR and CD8, to selectively activate CD8 Treg and enhance MTX-101's specificity, respectively. MTX-101 is designed to restore CD8 Treg functionality and the cytolytic elimination of pathogenic CD4 T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Type 1 Diabetes.
Learn more about Type 1 Diabetes Drugs opportunities in our groundbreaking Type 1 Diabetes research and development projects @ Type 1 Diabetes Unmet Needs [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Type 1 Diabetes Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
* Type 1 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.
Type 1 Diabetes Companies
Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Type 1 Diabetes Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Type 1 Diabetes treatment by visiting our website. Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Type 1 Diabetes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Type 1 Diabetes Pipeline Report
* Coverage- Global
* Type 1 Diabetes Companies- Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
* Type 1 Diabetes Pipeline Therapies- Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016 and others.
* Type 1 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Type 1 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Type 1 Diabetes Pipeline on our website @ Type 1 Diabetes Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Type 1 Diabetes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Type 1 Diabetes- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Teplizumab: Provention Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TTP 399: Novo Nordisk
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SBP 101: Takeda Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Eflornithine oral: Panbela Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Type 1 Diabetes Key Companies
* Type 1 Diabetes Key Products
* Type 1 Diabetes- Unmet Needs
* Type 1 Diabetes- Market Drivers and Barriers
* Type 1 Diabetes- Future Perspectives and Conclusion
* Type 1 Diabetes Analyst Views
* Type 1 Diabetes Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=type-1-diabetes-pipeline-drugs-report-2025-innovative-drug-developments-and-ongoing-clinical-studies-uncovered]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Type 1 Diabetes Pipeline Drugs Report 2025: Innovative Drug Developments and Ongoing Clinical Studies Uncovered here
News-ID: 4212639 • Views: …
More Releases from ABNewswire
Chronic Pulmonary Hypertension Market Report 2034: Epidemiology, Pipeline Therap …
Chronic Pulmonary Hypertension Prevalence is expected to rise, driven by aging populations, obesity trends, improved premature infant survival, environmental factors, genetic predisposition, enhanced diagnostics, and rising comorbidities.
DelveInsight's report, "Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of chronic pulmonary hypertension (CPH). The report covers historical and projected epidemiology and highlights market trends across key regions, including the United States, EU4 (Germany, France, Italy, Spain), the…
High Wire Payments Launches E-Check Solution for High-Risk Industries
High Wire Payments, a trusted name in the payment processing industry, has announced the launch of its innovative e-check solution, designed specifically to serve high-risk industries that often face challenges with traditional payment methods. This new offering reinforces the company's commitment to creating reliable, flexible, and accessible financial tools for businesses across complex markets.
Image: https://www.abnewswire.com/upload/2025/10/91c5e930a80a522f3ceb102f8571aa41.jpg
Understanding the hurdles many businesses face when trying to secure dependable payment processing, High Wire Payments…
From Code to Culture: SIPHIA Becomes the AI Rock Star of a Generation
SIPHIA has done it again, breaking barriers and expectations as she crosses the 500,000-view mark on TikTok, proving that the future of music is already here. An AI rock star born out of vision, innovation, and the unyielding belief in the power of technology fused with artistry, SIPHIA is not just a performer but a phenomenon. Her rise reflects the way music is evolving, where creativity is no longer confined…
Dr. Anil Shah Publishes Breakthrough in Rhinoplasty: Pyriform Aperture Enlargeme …
New York, NY - Dr. Anil Shah of Shah Aesthetics in Chicago, IL and Noses & Necks NYC recently published a peer-reviewed article titled "Pyriform Aperture Enlargement Through a Rhinoplasty Approach" in Aesthetic Surgery Journal Open Forum. Read the full article here: https://academic.oup.com/asjopenforum/article/doi/10.1093/asjof/ojae115/7907808
Advancing Rhinoplasty with Purpose
In his study, Dr. Shah describes how expanding the pyriform aperture-the bony opening at the base of the nose-allows surgeons to sculpt a refined external…
More Releases for Type
Pressure Pumping Market 2028 By Type, Well Type, Resource Type and Geography
The Insight Partners delivers well-researched industry-wide information on the Pressure Pumping market. It provides information on the market's essential aspects such as top participants, factors driving Pressure Pumping market growth, precise estimation of the Pressure Pumping market size, upcoming trends, changes in consumer behavioral pattern, market's competitive landscape, key market vendors, and other market features to gain an in-depth analysis of the market. Additionally, the report is a compilation of…
Lawn Mowers Market Analysis By Type, End User, Product Type, Fuel Type, Engine P …
Lawn Mowers Market Analysis By Type(Manual, Electric, Petrol, Robotic), By End User(Residential, Commercial), By Product Type(Walk behind Movers, Ride on Movers, Stand on Movers), By Fuel Type(Gas Powered, Propane Powered), By Engine Power(Less than 15 hp, Between 15hp and 30 hp, More than 30 hp), By Blade Type(Cylinder, Standard, Mulching, Lifting), By Drive Type(AWD, FWD, RWD), By Application(Residential, Professional landscaping, Golf Course, Government), By Distribution Channel(Retail Store, Online Website) &…
Automotive Exhaust System Component Market Type, Fuel Type, Treatment Device, Ve …
Automotive Exhaust System Component Market
This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering
Tenneco
Faurecia
Eberspacher
Boysen
Sango
HITER
Yutaka Giken
Calsonic Kansei
Magneti Marelli
Benteler
Sejong Industrial
Katcon
Futaba
Wanxiang
Bosal
Harbin Airui
Dinex
Catar
DSM
Get Sample PDF including full TOC, Tables and Figures @ https://www.ozonemarketreports.com/automotive-and-transportation/global-automotive-exhaust-system-components-market-professional-survey-report-2019/59563
On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
Exhaust Manifold
Exhaust Pipe
Catalytic Converter
Exhaust Temperature Sensor
Car Muffler
Exhaust…
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Automotive Electric Vacuum Pump Market By Type Diaphragm Type, Swing Piston Type …
Automatic electric vacuum pump is a device that gets the drive from the camshaft in the engine. It can also be run by alternator shaft in some designs. It’s an added benefit to any engine, which has high performance. The primary function of an automatic electric vacuum pump is to drain out the air from brake booster tank hence creating the vacuum, which in turn can be used for application…
Marine Composites Market |By Type |Resin Type|Vessel Type|Fiber Type |Region Ana …
The report includes market segmentation by composites type (metal matrix composite, ceramic matrix composite, polymer matrix composite); polymer matrix composite by fiber type (glass fiber, carbon fiber, others); polymer matrix composite by resin type (polyester, vinyl ester, epoxy, thermoplastic, others); vessel type (power boats, sailboats, cruise ships, others); and region (North America, Europe, APAC, Latin America, MEA).
Download Latest Free PDF Sample Brochure of “Marine Composites Market” With Detailed TOC…
